Ron Kessler

The Daiichi Sankyo deruxtecan (DXd) payload platform has revolutionized ADC therapy, enabling a series of highly active ADCs targeting HER2, HER3, TROP-2, and other targets. The DXd payload (a topoisomerase I inhibitor exatecan derivative) attached via cleavable tetrapeptide linker achieves high drug-antibody ratios and potent bystander effect. T-DXd (trastuzumab deruxtecan) has shown remarkable efficacy across HER2-positive, HER2-low, and HER2-ultralow breast cancer and other HER2-expressing cancers.